Questions? +1 (202) 335-3939 Login
Trusted News Since 1995
A service for energy industry professionals · Tuesday, March 19, 2024 · 697,041,925 Articles · 3+ Million Readers

Report: Exploring Fundamental Drivers Behind Sabre, Catalyst Pharmaceuticals, Renewable Energy Group, Luminex, Parker Drilling, and Apollo Endosurgery — New Horizons, Emerging Trends, and Upcoming Developments

NEW YORK, Dec. 11, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Sabre Corporation (NASDAQ:SABR), Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX), Renewable Energy Group, Inc. (NASDAQ:REGI), Luminex Corporation (NASDAQ:LMNX), Parker Drilling Company (NYSE:PKD), and Apollo Endosurgery, Inc. (NASDAQ:APEN), including updated fundamental summaries, consolidated fiscal reporting, and fully-qualified certified analyst research.

Complimentary Access: Research Reports

Full copies of recently published reports are available to readers at the links below.

SABR DOWNLOAD: http://Fundamental-Markets.com/register/?so=SABR
CPRX DOWNLOAD: http://Fundamental-Markets.com/register/?so=CPRX
REGI DOWNLOAD: http://Fundamental-Markets.com/register/?so=REGI
LMNX DOWNLOAD: http://Fundamental-Markets.com/register/?so=LMNX
PKD DOWNLOAD: http://Fundamental-Markets.com/register/?so=PKD
APEN DOWNLOAD: http://Fundamental-Markets.com/register/?so=APEN

(You may have to copy and paste the link into your browser and hit the [ENTER] key)

The new research reports from Fundamental Markets, available for free download at the links above, examine Sabre Corporation (NASDAQ:SABR), Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX), Renewable Energy Group, Inc. (NASDAQ:REGI), Luminex Corporation (NASDAQ:LMNX), Parker Drilling Company (NYSE:PKD), and Apollo Endosurgery, Inc. (NASDAQ:APEN) on a fundamental level and outlines the overall demand for their products and services in addition to an in-depth review of the business strategy, management discussion, and overall direction going forward. Several excerpts from the recently released reports are available to today's readers below.

-----------------------------------------

Important Notice: the following excerpts are not designed to be standalone summaries and as such, important information may be missing from these samples. Please download the entire research report, free of charge, to ensure you are reading all relevant material information. All information in this release was accessed December 7th, 2018. Percentage calculations are performed after rounding. All amounts in millions (MM), except per share amounts.

-----------------------------------------

SABRE CORPORATION (SABR) REPORT OVERVIEW

Sabre's Recent Financial Performance

For the three months ended September 30th, 2018 vs September 30th, 2017, Sabre reported revenue of $970.28MM vs $900.61MM (up 7.74%) and analysts estimated basic earnings per share $0.26 vs $0.33 (down 21.21%). For the twelve months ended December 31st, 2017 vs December 31st, 2016, Sabre reported revenue of $3,598.48MM vs $3,373.39MM (up 6.67%) and analysts estimated basic earnings per share $0.87 vs $0.87 (unchanged). Analysts expect earnings to be released on February 13th, 2019. The report will be for the fiscal period ending December 31st, 2018. The reported EPS for the same quarter last year was $0.29. The estimated EPS forecast for the next fiscal year is $1.45 and is expected to report on February 13th, 2019.

To read the full Sabre Corporation (SABR) report, download it here: http://Fundamental-Markets.com/register/?so=SABR

-----------------------------------------

CATALYST PHARMACEUTICALS, INC. (CPRX) REPORT OVERVIEW

Catalyst Pharmaceuticals' Recent Financial Performance

For the twelve months ended December 31st, 2017 vs December 31st, 2016, Catalyst Pharmaceuticals reported revenue of $0.00MM vs $0.00MM and analysts estimated basic earnings per share -$0.21 vs -$0.22. Analysts expect earnings to be released on March 13th, 2019. The report will be for the fiscal period ending December 31st, 2018. Reported EPS for the same quarter last year was -$0.06. The estimated EPS forecast for the next fiscal year is -$0.16 and is expected to report on March 13th, 2019.

To read the full Catalyst Pharmaceuticals, Inc. (CPRX) report, download it here: http://Fundamental-Markets.com/register/?so=CPRX

-----------------------------------------

RENEWABLE ENERGY GROUP, INC. (REGI) REPORT OVERVIEW

Renewable Energy Group's Recent Financial Performance

For the three months ended September 30th, 2018 vs September 30th, 2017, Renewable Energy Group reported revenue of $597.75MM vs $626.98MM (down 4.66%) and analysts estimated basic earnings per share $0.65 vs -$0.29. For the twelve months ended December 31st, 2017 vs December 31st, 2016, Renewable Energy Group reported revenue of $2,158.24MM vs $2,041.23MM (up 5.73%) and analysts estimated basic earnings per share -$2.04 vs $1.06. Analysts expect earnings to be released on March 14th, 2019. The report will be for the fiscal period ending December 31st, 2018. Reported EPS for the same quarter last year was -$0.44. The estimated EPS forecast for the next fiscal year is $2.05 and is expected to report on March 14th, 2019.

To read the full Renewable Energy Group, Inc. (REGI) report, download it here: http://Fundamental-Markets.com/register/?so=REGI

-----------------------------------------

LUMINEX CORPORATION (LMNX) REPORT OVERVIEW

Luminex's Recent Financial Performance

For the three months ended September 30th, 2018 vs September 30th, 2017, Luminex reported revenue of $72.45MM vs $74.14MM (down 2.28%) and basic earnings per share $0.04 vs $0.40 (down 90.00%). For the twelve months ended December 31st, 2017 vs December 31st, 2016, Luminex reported revenue of $306.57MM vs $270.64MM (up 13.28%) and analysts estimated basic earnings per share $0.67 vs $0.32 (up 109.38%). Analysts expect earnings to be released on February 11th, 2019. The report will be for the fiscal period ending December 31st, 2018. The reported EPS for the same quarter last year was $0.17. The estimated EPS forecast for the next fiscal year is $0.54 and is expected to report on February 11th, 2019.

To read the full Luminex Corporation (LMNX) report, download it here: http://Fundamental-Markets.com/register/?so=LMNX

-----------------------------------------

PARKER DRILLING COMPANY (PKD) REPORT OVERVIEW

Parker Drilling's Recent Financial Performance

For the three months ended September 30th, 2018 vs September 30th, 2017, Parker Drilling reported revenue of $123.40MM vs $118.31MM (up 4.30%) and analysts estimated basic earnings per share -$7.70 vs -$2.30. For the twelve months ended December 31st, 2017 vs December 31st, 2016, Parker Drilling reported revenue of $442.52MM vs $427.00MM (up 3.63%) and analysts estimated basic earnings per share -$13.34 vs -$27.89. Analysts expect earnings to be released on February 13th, 2019. The report will be for the fiscal period ending December 31st, 2018.

To read the full Parker Drilling Company (PKD) report, download it here: http://Fundamental-Markets.com/register/?so=PKD

-----------------------------------------

APOLLO ENDOSURGERY, INC. (APEN) REPORT OVERVIEW

Apollo Endosurgery's Recent Financial Performance

For the three months ended September 30th, 2018 vs September 30th, 2017, Apollo Endosurgery reported revenue of $14.14MM vs $16.54MM (down 14.52%) and analysts estimated basic earnings per share -$0.45 vs -$0.32. For the twelve months ended December 31st, 2017 vs December 31st, 2016, Apollo Endosurgery reported revenue of $64.31MM vs $64.65MM (down 0.53%) and analysts estimated basic earnings per share -$2.01 vs -$105.69. Analysts expect earnings to be released on March 7th, 2019. The report will be for the fiscal period ending December 31st, 2018. The reported EPS for the same quarter last year was -$0.42. The estimated EPS forecast for the next fiscal year is -$1.17 and is expected to report on March 7th, 2019.

To read the full Apollo Endosurgery, Inc. (APEN) report, download it here: http://Fundamental-Markets.com/register/?so=APEN

-----------------------------------------

ABOUT FUNDAMENTAL MARKETS

Fundamental Markets serves thousands of members and have provided research through some of the world's leading brokerages for over a decade–and continue to be one of the best information sources for investors and investment professionals worldwide. Fundamental Markets' roster boasts decades of financial experience and includes top financial writers, FINRA® BrokerCheck® certified professionals with current and valid CRD® number designations, as well as Chartered Financial Analyst® (CFA®) designation holders, to ensure up to date factual information for active readers on the topics they care about.

REGISTERED MEMBER STATUS

Fundamental Markets' oversight and audit staff are registered analysts, brokers, and/or financial advisers ("Registered Members") working within Equity Research, Media, and Compliance departments. Fundamental Markets' roster includes qualified CFA® charterholders, licensed securities attorneys, and registered FINRA® members holding duly issued CRD® numbers. Current licensed status of several Registered Members at Fundamental Markets have been independently verified by an outside audit firm, including policy and audit records duly executed by Registered Members. Complaints, concerns, questions, or inquiries regarding this release should be directed to Fundamental Markets' Compliance department by Phone, at +1 667-401-0010, or by E-mail at compliance@Fundamental-Markets.com.

LEGAL NOTICES

Information contained herein is not an offer or solicitation to buy, hold, or sell any security. Fundamental Markets, Fundamental Markets members, and/or Fundamental Markets affiliates are not responsible for any gains or losses that result from the opinions expressed. Fundamental Markets makes no representations as to the completeness, accuracy, or timeliness of the material provided and all materials are subject to change without notice. Fundamental Markets has not been compensated for the publication of this press release by any of the above mentioned companies. Fundamental Markets is not a financial advisory firm, investment adviser, or broker-dealer, and does not undertake any activities that would require such registration. For our full disclaimer, disclosure, and terms of service please visit our website.

Media Contact:
Andrew Duffie, Media Department
Office: +1 667-401-0010
E-mail: media@Fundamental-Markets.com

© 2018 Fundamental Markets. All Rights Reserved. For republishing permissions, please contact a partner network manager at partnership@Fundamental-Markets.com.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

FINRA®, BrokerCheck®, and CRD® are registered trademarks owned by Financial Industry Regulatory Authority, Inc.

Powered by EIN News


EIN Presswire does not exercise editorial control over third-party content provided, uploaded, published, or distributed by users of EIN Presswire. We are a distributor, not a publisher, of 3rd party content. Such content may contain the views, opinions, statements, offers, and other material of the respective users, suppliers, participants, or authors.

Submit your press release